Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CheckMate 8HW: Nivolumab +/- Ipilimumab vs Chemotherapy in MSI-H/dMMR Metastatic Colorectal Cancer
NCT04008030Phase 3Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2019
- Primary completion
- Aug 2024
- Modality
- Monoclonal Antibodies
- Countries
- 24
01
Overview
A Phase 3 trial of nivolumab in colorectal cancer (CRC), sponsored by Bristol Myers Squibb. Started Aug 2019; status: active, not recruiting.
02
Drugs
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04008030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04008030.